Apnimed, Inc.
As seen on the 24/7 Wall St. homepage on July 27, 2026.
Apnimed, Inc.
APMD · Nasdaq
$14–$16 / share
$150M raise
10,000,000 shares
Apnimed amended its S-1 registration statement.
Sleep apnea drugmaker Apnimed is locked and loaded for its $150 million Nasdaq debut, pricing the offering at $14 to $16 per share as it brings a pill-based alternative to the CPAP machine market.
Mentioned: APMD